Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
On Thursday, the public had the first chance to air their grievances about the FDA’s controversial Commissioner’s National Priority Voucher (CNPV) pilot program, the flagship initiative of recently | On Thursday, the public had the first chance to air their grievances about the FDA’s controversial Commissioner’s National Priority Voucher (CNPV) pilot program, the flagship initiative of recently departed agency leader Marty Makary, M.D.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Industry seeks more clarity on commissioner's voucher program

Drug companies, patient groups urge FDA to pause commissioner’s voucher program

Accelerating Targeted Gene Expression Analysis in Drug Development

FDA issues untitled letter after finding ‘eye-catching graphics’ in promotional emails

As Akeso takes center stage at ASCO, China biotech industry cements its coming of age

Pharma and rare disease advocates press FDA at public hearing on Makary's National Priority Voucher pilot, urging formal…

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has…

Pfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the | Pfizer’s complaint…

From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with…

The White House has used the program to reward companies that help its political goals.

With the FDA now rudderless following the revelation that commissioner Marty Makary, M.D., is stepping down, voices across…